医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia

2022年08月11日 PM09:00
このエントリーをはてなブックマークに追加


 

MALVERN, Pa. & BRISBANE, Australia

Alliance Pharma (Alliance), a global leader in bioanalytical and CMC testing services in the pharmaceutical and biopharmaceutical industry, today announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005051/en/

Alliance Pharma’s new laboratory facility in Brisbane, Australia, that’s opening in November 2022 to support preclinical and clinical phase bioanalytical research. (Photo: Business wire)

Alliance Pharma’s new laboratory facility in Brisbane, Australia, that’s opening in November 2022 to support preclinical and clinical phase bioanalytical research. (Photo: Business wire)

Alliance Pharma Pty, Ltd. will contain an expansive state-of-the-art lab, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will now also be able to transfer methods and maintain continuous project management across their global bioanalytical sites in the U.S. and Europe. Alliance’s opening of the Australian site closely follows their recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC.

“With the speed to start Phase I studies, quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” said Alliance CCO Vito Saccente. “Alliance will not only be able to provide services critical to this market, but also when these compounds move to Phase II, we are well-positioned to transfer methods without losing critical knowledge and can continue to support the progression of clinical development for our clients.”

Alliance Pharma Pty, Ltd. President Hao (Jason) Wang, Ph.D., will be leading an experienced team of scientists to provide broad range bioanalytical services. This new lab is outfitted with the latest LC-MS, ligand binding, flow cytometry, ELISpot and PCR instrumentation to support early and late phase research and will be capable of de novo method development, method transfers, method validation and sample analysis for pharmacokinetic (PK), biomarkers and immunogenicity.

About Alliance Pharma

Founded in 2008, Alliance is a contract research organization (CRO) with bioanalytical and CMC testing labs in Malvern, PA, Brisbane, AU, Cambridge, UK and Sandwich, UK. The labs specialize in advanced research services for all drug molecules, cell and gene therapies, and drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance’s mission is to build a trusted partnership with our clients to support their successful drug development programs. Our business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005051/en/

CONTACT

Lindsey Langemeier

SCORR Marketing

+1 402-405-4269

lindsey@scorrmarketing.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Actylis首次亮相,标志着全球特种成分生产和采购一体化巨头的诞生
  • バイオサイトジェンがBioJapan2022に参加し、革新的な研究開発プラットフォーム、二重特異性ADCプログラム、パイプラインの進捗を紹介へ
  • “3D print x craftsmanship” Achieved 200% in three days since eyewear brand “HYPHEN” has started crowdfunding by using KICKSTARTER
  • PHCと三和化学研究所が共同開発した、穿刺から廃棄までワンボタンで操作できる採血用穿刺器具「ソフレット®」を発売
  • Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress